Abstract
We are facing and extremely exciting era after knowing the results of the recently finished clinical trials on the effectiveness of endovascular thrombectomy in acute stroke patients with large vessel occlusion [1-3]. The MRCLEAN, ESCAPE, EXTEND-IA and SWIFT-PRIME trials showed that a significant proportion of patients with acute stroke may greatly benefit from endovascular thrombectomy with the current generation of stentriever devices and these results are expected to be confirmed by the REVASCAT trial [4] to be presented in the upcoming European Stroke Organization Conference in Glasgow next April. One of the most interesting aspects of these studies is that patients with poor prognostic factors such as advanced age or tandem occlusions also benefit from endovascular thrombectomy, because their functional outcome is terrible when only medical therapy is used.
Highlights
We are facing and extremely exciting era after knowing the results of the recently finished clinical trials on the effectiveness of endovascular thrombectomy in acute stroke patients with large vessel occlusion [13]
The MRCLEAN, ESCAPE, EXTEND-IA and SWIFT-PRIME trials showed that a significant proportion of patients with acute stroke may greatly benefit from endovascular thrombectomy with the current generation of stentriever devices and these results are expected to be confirmed by the REVASCAT trial [4] to be presented in the upcoming European Stroke Organization Conference in Glasgow April
One of the most interesting aspects of these studies is that patients with poor prognostic factors such as advanced age or tandem occlusions benefit from endovascular thrombectomy, because their functional outcome is terrible when only medical therapy is used
Summary
We are facing and extremely exciting era after knowing the results of the recently finished clinical trials on the effectiveness of endovascular thrombectomy in acute stroke patients with large vessel occlusion [13]. The MRCLEAN, ESCAPE, EXTEND-IA and SWIFT-PRIME trials showed that a significant proportion of patients with acute stroke may greatly benefit from endovascular thrombectomy with the current generation of stentriever devices and these results are expected to be confirmed by the REVASCAT trial [4] to be presented in the upcoming European Stroke Organization Conference in Glasgow April.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
